A number of firms have modified their ratings and price targets on shares of LeMaitre Vascular (NASDAQ: LMAT) recently:

  • 11/1/2017 – LeMaitre Vascular was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “LEMAITRE VASCULAR, INC. is a leading global provider of innovative devices for the treatment of peripheral vascular disease. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. “
  • 10/31/2017 – LeMaitre Vascular was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $35.00 price target on the stock. According to Zacks, “LEMAITRE VASCULAR, INC. is a leading global provider of innovative devices for the treatment of peripheral vascular disease. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. “
  • 10/29/2017 – LeMaitre Vascular had its “buy” rating reaffirmed by analysts at Stifel Nicolaus.
  • 10/27/2017 – LeMaitre Vascular was downgraded by analysts at Benchmark Co. from a “buy” rating to a “hold” rating.
  • 10/27/2017 – LeMaitre Vascular was downgraded by analysts at First Analysis from an “overweight” rating to an “equal weight” rating. They now have a $34.00 price target on the stock.
  • 10/27/2017 – LeMaitre Vascular had its price target lowered by analysts at Canaccord Genuity from $30.00 to $29.00. They now have a “hold” rating on the stock.
  • 10/9/2017 – LeMaitre Vascular had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $30.00 price target on the stock.
  • 9/28/2017 – LeMaitre Vascular was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “LEMAITRE VASCULAR, INC. is a leading global provider of innovative devices for the treatment of peripheral vascular disease. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. “

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.05. LeMaitre Vascular had a return on equity of 16.16% and a net margin of 15.81%. The company had revenue of $24.80 million for the quarter, compared to analysts’ expectations of $25.49 million. During the same period in the previous year, the business posted $0.17 earnings per share. The business’s quarterly revenue was up 6.9% compared to the same quarter last year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 7th. Investors of record on Wednesday, November 22nd will be issued a $0.055 dividend. This represents a $0.22 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend is Tuesday, November 21st. LeMaitre Vascular’s payout ratio is presently 28.57%.

In related news, CEO George W. Lemaitre sold 11,300 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $32.79, for a total value of $370,527.00. Following the sale, the chief executive officer now directly owns 3,405,508 shares in the company, valued at $111,666,607.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman George W. Lemaitre sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $33.65, for a total value of $1,009,500.00. Following the completion of the sale, the chairman now owns 3,436,808 shares in the company, valued at $115,648,589.20. The disclosure for this sale can be found here. Insiders sold 237,537 shares of company stock worth $8,251,182 over the last quarter. 23.70% of the stock is currently owned by company insiders.

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Receive News & Ratings for LeMaitre Vascular Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc and related companies with MarketBeat.com's FREE daily email newsletter.